{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:31:24Z","timestamp":1793968284876,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,9]],"date-time":"2027-10-09T00:00:00Z","timestamp":1823040000000},"content-version":"am","delay-in-days":312,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2P30CA124435-16"],"award-info":[{"award-number":["2P30CA124435-16"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA283888"],"award-info":[{"award-number":["R35CA283888"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["CLIN2-12595"],"award-info":[{"award-number":["CLIN2-12595"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006315","name":"CureSearch for Children's Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA263500"],"award-info":[{"award-number":["R01CA263500"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["Scale Ready Grant Program"],"award-info":[{"award-number":["Scale Ready Grant Program"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006352","name":"Virginia and D.K. Ludwig Fund for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcyt.2026.102970","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:28:53Z","timestamp":1785367733000},"page":"102970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated T-cell enrichment, static transduction, and expansion in gas-permeable bioreactors for adoptive cell therapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-0926","authenticated-orcid":false,"given":"Nikolaos","family":"Gkitsas-Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan J.","family":"Retherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3003-0174","authenticated-orcid":false,"given":"Carely","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota D.","family":"Klysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7031-0535","authenticated-orcid":false,"given":"Andrew","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Fick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette Mata","family":"Alcazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Monje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-3860","authenticated-orcid":false,"given":"Steven A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8313-6197","authenticated-orcid":false,"given":"Ramya H.","family":"Tunuguntla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102970_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102970_bib0002","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcyt.2026.102970_bib0003","first-page":"155","article-title":"Programming CAR-T cells to kill cancer","volume":"22","author":"Labanieh","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2026.102970_bib0004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2026.102970_bib0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/cgt.2014.78","article-title":"Towards a commercial process for the manufacture of genetically modified T cells for therapy","volume":"22","author":"Kaiser","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102970_bib0006","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jcyt.2026.102970_bib0007","first-page":"1051","article-title":"The business case for cell and gene therapies","volume":"39","author":"Abou-El-Enein","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102970_bib0008","doi-asserted-by":"crossref","first-page":"200980","DOI":"10.1016\/j.omton.2025.200980","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.jcyt.2026.102970_bib0009","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102970_bib0010","first-page":"1183","article-title":"GD2-directed CAR T cells for neuroblastoma: a phase 1 clinical trial","volume":"28","author":"Majzner","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102970_bib0027","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102970_bib0014","first-page":"162","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"365","author":"Weber","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102970_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.17","article-title":"Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells","volume":"2","author":"Fenard","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jcyt.2026.102970_bib0016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","article-title":"Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products","volume":"26","author":"Cornetta","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102970_bib0018","unstructured":"Takara Bio. RetroNectin reagent protocol. Cat. No. T100A\/B. 2017. https:\/\/www.takara.co.kr\/file\/manual\/pdf\/T100A_B_e.v1705.pdf Accessed August 21, 2026"},{"key":"10.1016\/j.jcyt.2026.102970_bib0019","article-title":"An efficient large-scale retroviral transduction method involving preloading of retroviral vector into fibronectin-coated bag","volume":"1","author":"Dodo","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102970_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00221","article-title":"Differential expression of immune checkpoint modulators on in vitro primed CD4\u207a and CD8\u207a T cells","volume":"7","author":"Sabins","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102970_bib0021","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/bloodadvances.2020003080","article-title":"Functional characterization of PD1\u207aTIM3\u207a tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade","volume":"5","author":"Roussel","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102970_bib0022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102970_bib0023","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2026.102970_bib0024","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s11684-024-1071-9","article-title":"Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma","volume":"18","author":"Zou","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.jcyt.2026.102970_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12915-022-01266-7","article-title":"Fluid shear stress enhances T cell activation through Piezo1","volume":"20","author":"Hope","year":"2022","journal-title":"BMC Biol"},{"key":"10.1016\/j.jcyt.2026.102970_bib0031","doi-asserted-by":"crossref","first-page":"109999","DOI":"10.1016\/j.isci.2024.109999","article-title":"Enhanced and sustained T cell activation in response to fluid shear stress","volume":"27","author":"Sarna","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.jcyt.2026.102970_bib0032","series-title":"ICH harmonised guideline Q8(R2): pharmaceutical development","article-title":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2009"},{"key":"10.1016\/j.jcyt.2026.102970_bib0033","series-title":"4 version","article-title":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline Q11: development and manufacture of drug substances\u2014chemical entities and biotechnological\/biological entities. Step","year":"2012"},{"key":"10.1016\/j.jcyt.2026.102970_bib0034","series-title":"European public assessment reports: background and context","year":"2018"},{"key":"10.1016\/j.jcyt.2026.102970_bib0026","first-page":"1801","article-title":"Academic GMP manufacturing of CAR T cells","volume":"11","author":"Mock","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102970_bib0028","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-024-03035-1","article-title":"Enhancing pediatric access to cell and gene therapies","volume":"30","author":"Mackall","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102970_bib0029","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-024-07800-7","article-title":"A roadmap for affordable genetic medicines","volume":"634","author":"Kliegman","year":"2024","journal-title":"Nature"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600931X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600931X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:23:06Z","timestamp":1793967786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492600931X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S146532492600931X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102970","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated T-cell enrichment, static transduction, and expansion in gas-permeable bioreactors for adoptive cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102970"}}